Drug classes

36 values

SearchDisplay

Resolved through each product's ATC code (legacy codes are mapped to current ones first).

Class	ATC prefixes	Search terms	Drugs in the data
PD-1/PD-L1 inhibitors `pd1`	`L01FF, L01FY02`	pd-1, pd1, anti-pd-1, anti-pd-l1, pd-1 inhibitor, pd-l1 inhibitor	atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, nivolumab, pembrolizumab, relatlimab;nivolumab, retifanlimab, serplulimab, sugemalimab, tislelizumab, toripalimab
CTLA-4 inhibitors `ctla4`		ctla-4, ctla4, anti-ctla-4, ctla-4 inhibitor	ipilimumab, tremelimumab
Immune checkpoint inhibitors `checkpoint`	`L01FF, L01FY02`	checkpoint inhibitor, checkpoint inhibitors, immune checkpoint inhibitor, ici, io, immunotherapy	atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab;nivolumab, retifanlimab, serplulimab, sugemalimab, tislelizumab, toripalimab, tremelimumab
PARP inhibitors `parp`	`L01XK`	parp, parpi, parp inhibitor, parp inhibitors, parp-inhibitor	niraparib, niraparib;abiraterone, olaparib, rucaparib, talazoparib
CDK4/6 inhibitors `cdk46`	`L01EF`	cdk4/6, cdk 4/6, cdk4/6 inhibitor, cdk inhibitor	abemaciclib, palbociclib, ribociclib
EGFR inhibitors `egfr`	`L01EB, L01FE`	egfr inhibitor, egfr inhibitors, anti-egfr therapy	afatinib, cetuximab, dacomitinib, erlotinib, gefitinib, lazertinib, osimertinib, panitumumab
EGFR tyrosine kinase inhibitors `egfr-tki`	`L01EB`	egfr tki, egfr-tki	afatinib, dacomitinib, erlotinib, gefitinib, lazertinib, osimertinib
ALK inhibitors `alk-tki`	`L01ED`	alk inhibitor, alk tki, alk-tki	alectinib, brigatinib, ceritinib, crizotinib, lorlatinib
BRAF inhibitors `braf-i`	`L01EC`	braf inhibitor, brafi	dabrafenib, encorafenib, tovorafenib, vemurafenib
MEK inhibitors `mek-i`	`L01EE`	mek inhibitor, meki, mek	binimetinib, cobimetinib, mirdametinib, selumetinib, trametinib
BCR::ABL1 tyrosine kinase inhibitors `bcr-abl-tki`	`L01EA`	bcr-abl tki, abl tki, abl inhibitor	asciminib, bosutinib, dasatinib, imatinib, nilotinib, ponatinib
BTK inhibitors `btk-i`	`L01EL`	btk, btki, btk inhibitor	acalabrutinib, ibrutinib, pirtobrutinib, zanubrutinib
HER2-directed therapies `her2`	`L01FD, L01EH, L01FY01`	anti-her2, her2-directed, her2 targeted, her2-targeted therapy	lapatinib, neratinib, pertuzumab, pertuzumab;trastuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, tucatinib, zanidatamab
HER2-directed antibodies and ADCs `her2-ab`	`L01FD, L01FY01`	her2 antibody, anti-her2 antibody	pertuzumab, pertuzumab;trastuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, zanidatamab
HER2 tyrosine kinase inhibitors `her2-tki`	`L01EH`	her2 tki, her2-tki	lapatinib, neratinib, tucatinib
Anti-CD20 antibodies `cd20-ab`	`L01FA`	anti-cd20, cd20 antibody	obinutuzumab, rituximab
Anti-CD38 antibodies `cd38-ab`	`L01FC`	anti-cd38, cd38 antibody	daratumumab, isatuximab
Anti-EGFR antibodies `egfr-ab`	`L01FE`	anti-egfr, egfr antibody	cetuximab, panitumumab
VEGF/VEGFR inhibitors `vegf`	`L01FG, L01EK`	vegf, vegfr, anti-vegf, anti-angiogenic, antiangiogen	aflibercept, axitinib, bevacizumab, cabozantinib, fruquintinib, lenvatinib, nintedanib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, tivozanib, vandetanib
VEGFR tyrosine kinase inhibitors `vegfr-tki`	`L01EK`	vegfr tki, vegfr-tki, vegfr inhibitor, multikinase inhibitor	axitinib, cabozantinib, fruquintinib, lenvatinib, nintedanib, pazopanib, regorafenib, sorafenib, sunitinib, tivozanib, vandetanib
mTOR inhibitors `mtor`	`L01EG`	mtor, mtor inhibitor	everolimus, temsirolimus
JAK inhibitors `jak`	`L01EJ`	jak inhibitor, jaki	fedratinib, momelotinib, ruxolitinib
PI3K inhibitors `pi3k`	`L01EM`	pi3k, pi3k inhibitor	alpelisib, idelalisib, inavolisib
FGFR inhibitors `fgfr-i`	`L01EN`	fgfr inhibitor	erdafitinib, futibatinib, pemigatinib
MET inhibitors `met-i`		met inhibitor, met tki	capmatinib, tepotinib
IDH inhibitors `idh-i`	`L01XM`	idh inhibitor	ivosidenib, vorasidenib
HDAC inhibitors `hdac`	`L01XH`	hdac, hdac inhibitor	panobinostat
Hedgehog pathway inhibitors `hedgehog`	`L01XJ`	hedgehog, hedgehog inhibitor, smo inhibitor	glasdegib, sonidegib, vismodegib
Proteasome inhibitors `proteasome`	`L01XG`	proteasome inhibitor, proteasome	bortezomib, carfilzomib, ixazomib
Antibody-drug conjugates `adc`		adc, adcs, antibody-drug conjugate, antibody drug conjugate, antibody-drug conjugates	belantamab mafodotin, brentuximab vedotin, datopotamab deruxtecan, enfortumab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin, loncastuximab tesirine, mirvetuximab soravtansine, polatuzumab vedotin, sacituzumab govitecan, tisotumab vedotin, trastuzumab deruxtecan, trastuzumab emtansine
Bispecific antibodies `bispecific`		bispecific, bispecifics, bispecific antibody, bispecific antibodies, t-cell engager, t cell engager	amivantamab, blinatumomab, catumaxomab, elranatamab, epcoritamab, glofitamab, linvoseltamab, mosunetuzumab, odronextamab, talquetamab, tarlatamab, teclistamab, zanidatamab
CAR-T and other cell therapies `cell-therapy`		car-t, car t, cart, car-t cells, cell therapy	axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel, obecabtagene autoleucel, tabelecleucel, tisagenlecleucel
Immunomodulatory drugs (IMiDs) `imid`		imid, imids, immunomodulatory drug, immunomodulatory drugs, immunomodulators	lenalidomide, pomalidomide, thalidomide
Interferons `interferon`	`L03AB`	interferon, interferons, peginterferon, pegylated interferon	peginterferon alfa-2a, ropeginterferon alfa-2b
Radioligand therapies `radioligand`	`V10XX`	radioligand, radioligands, radioligand therapy, radionuclide therapy, prrt, lutetium	lutetium (177Lu) oxodotreotide, lutetium (177Lu) vipivotide tetraxetan, radium Ra223 dichloride
Endocrine therapies `endocrine`	`L02`	endocrine therapy, hormone therapy, antihormonal, adt	abiraterone, apalutamide, camizestrant, darolutamide, degarelix, elacestrant, enzalutamide, fulvestrant, imlunestrant, leuprorelin, niraparib;abiraterone, relugolix, toremifene